Status:
COMPLETED
A Comparison of Recombinant Human Brain Natriuretic Peptide and Dobutamine
Lead Sponsor:
Nantong University
Conditions:
Acute Decompensated Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
To compare the therapeutic efficacy of recombinant human brain natriuretic peptide (rhBNP) with dobutamine on acute decompensated heart failure patients with different blood BNP levels
Detailed Description
Patients with acute decompensated heart failure (ADHF) whose left ventricular ejection fraction(LVEF) was \<40%, were assigned to a high BNP group (BNP ≤ 3000 pg/mL) or an extra-high BNP group (BNP \>...
Eligibility Criteria
Inclusion
- patients were classified as NYHA class III-IV
- ejection fraction \<40%
Exclusion
- intravenous administration with rhBNP or dobutamine in the 2 weeks before study entry
- acute myocardial infarction
- significant valvular stenosis
- serious ventricular arrhythmia (frequent ventricular premature beat of \>5 bpm, nonsustained and sustained ventricular tachycardia)
- blood pressure \<95/60 mmHg or \>140/90 mmHg
- shock
- hypovolemia
- hepatic or renal impairment
- pregnant and lactating women.
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT01837849
Start Date
January 1 2011
End Date
June 1 2012
Last Update
April 23 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.